Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial

Background: MAVORIC, a phase 3, randomized trial, evaluated mogamulizumab (Moga) safety and efficacy vs vorinostat (Vori) in patients (pts) with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS) (NCT01728805). Moga-associated rash (MAR) was the second most common TEAE in the Moga treatment arm and most common TEAE leading to treatment discontinuation (7% discontinuation rate, 13/184). Grade 1–2 and 3 drug rashes (DR) occurred in 20% (36/184) and 4% (8/184) of Moga pts, respectively.